Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 17/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 17/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 17/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25481624 | 0.86 | HSD11B1 (0.37) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL108483 | 0.86 | HSD11B1 (0.37) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14681899 | 0.82 | CHRNB2 (0.32) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10200629 | 0.80 | ATM (0.31) | ATM | |
| SCHEMBL20154470 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14805917 | 0.74 | ATM (0.37) | ATM | |
| SCHEMBL14681898 | 0.74 | HSD11B1 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15032326 | 0.74 | HSD11B1 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15032325 | 0.74 | HSD11B1 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25450798 | 0.72 | ATM (0.35) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170267696-A1 | CERTAIN PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267696-A1 | CERTAIN PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-8946422-B2 | 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120040959-A1 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8044204-B2 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | FLT3, ABL1, FLI1 | CHRNB2 4584/4885CHRNA3 4168/4885CHRNA4 4030/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | CHRNB2 3731/4885CHRNA3 3537/4885CHRNA4 3945/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | CHRNB2 4055/4885CHRNA3 3645/4885CHRNA4 3953/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | CHRNB2 4751/4885CHRNA3 4831/4885CHRNA4 4842/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | CHRNB2 4568/4885CHRNA3 4559/4885CHRNA4 4673/4885 |
| US-20170267696-A1 | CERTAIN PROTEIN KINASE INHIBITORS | CDK4, CDK6, CDK2 | CHRNB2 4861/4885CHRNA3 4865/4885CHRNA4 4874/4885 |
| US-20120040959-A1 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | TOP1, TOP2B, DNA2 | CHRNB2 4515/4885CHRNA3 4470/4885CHRNA4 4503/4885 |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | ROS1, ALK, ROR1 | CHRNB2 3520/4885CHRNA3 2587/4885CHRNA4 3288/4885 |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | TOP1, TOP2B, DNA2 | CHRNB2 4515/4885CHRNA3 4470/4885CHRNA4 4503/4885 |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA3 1700/4885CHRNA4 1977/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | CHRNB2 4252/4885CHRNA3 4374/4885CHRNA4 4592/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA3 1700/4885CHRNA4 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.